Demographic data for the randomised study participants
| Total | Treatment group | |||||
| Placebo | 50 µg·day−1 | 100 µg·day−1 | 200 µg·day−1 | 500 µg·day−1 | ||
| Number of patients n | 65 | 13 | 14 | 14 | 12 | 12 |
| Number switched to 1000 µg·day−1 | 25 | 6 | 5 | 8 | 4 | 2 |
| Male:female | 22:43 | 4:9 | 6:8 | 7:7 | 2:10 | 3:9 |
| Age yrs (range) | 42.4 (19–64) | 42.5 (19–61) | 43.3 (19–63) | 44.7 (21–59) | 41.2 (24–60) | 39.6 (19–64) |
| Duration of asthma yrs (range) | 27.0 (4–60) | 30.3 (4–60) | 30.6 (6–60) | 22.5 (4–48) | 31.2 (12–55) | 20.2 (4–40) |
| Skin test positive n (%) | 60 (92.3) | 12 (92.3) | 14 (100) | 12 (85.7) | 12 (100) | 10 (83.3) |
| Exsmokers:nonsmokers | 9:56 | 2:11 | 1:13 | 2:12 | 1:11 | 3:9 |
| ICS dose µg·day−1 (BDP equivalent) | 658 (100–1600) | 731 (100–1600) | 550 (200–1000) | 700 (200–1600) | 671 (200–1000) | 642 (200–1000) |
| FEV1 L | 2.81 (2.61–3.00) | 2.50 (2.07–2.94) | 2.91 (2.39–3.45) | 2.94 (2.42–3.45) | 2.62 (2.15–3.09) | 3.04 (2.60–3.48) |
| FEV1 % pred | 90.8 (86.3–95.2) | 83.7 (71.3–96.1) | 91.0 (82.1–99.8) | 91.9 (82.2–101.5) | 85.2 (71.6–98.8) | 102.5 (93.9–111.0) |
| FEV1/FVC % | 70.8 (68.1–73.6) | 68.3 (59.5–77.1) | 70.6 (64.4–76.7) | 69.1 (62.2–76.0) | 69.7 (63.2–76.3) | 76.9 (72.2–81.5) |
Data are presented as mean (95% confidence intervals) unless otherwise stated
ICS: inhaled corticosteroids
BDP: beclomethasone
FEV1: forced expiratory volume in one second
FVC: forced vital capacity